Analysed KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) News Sources
KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach
16-04-2026
marketbeat.com
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
08-04-2026
yahoo.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial
01-04-2026
yahoo.com
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
30-03-2026
yahoo.com
KalVista Pharmaceuticals Inc (KALV) Q4 2025 Earnings Call Highlights: Strong Launch of EKTERLY ...
25-03-2026
yahoo.com
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
25-03-2026
yahoo.com
What is the current price of KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ)?
The current price of KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) is $19.43.
KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) absolute price change since previous trading day?
The absolute price change of KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) since the previous trading day is $-1.44.
KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) percentage price change since previous trading day?
The percentage price change of KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) since the previous trading day is -6.8999%.
What is the most recent average sentiment score for KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ)?
The most recent average sentiment score for KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ)?
The most recent sentiment for KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ) is .
SEC-8K** Filing Available For KALVISTA PHARMACEUTICALS INC (KALV:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.